INO
Inovio Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Inovio Pharmaceuticals has 2 disclosed suppliers and 5 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceAll revenue was derived under the collaborative arrangement with ApolloBio for the years ended December 31, 2025 and 2024 .
basisINO FY2025 revenue $65,343
INO 10-Kaccession 0001055726-26-000008
SentenceIn addition, we previously relied on VGXI to manufacture DNA plasmids for our DNA medicine candidates before they became unable to produce the necessary plasmids due to a lack of manufacturing capacity.
INO 10-Kaccession 0001055726-26-000008
SentenceWe have entered into agreements with government agencies, such as the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIH NIAID), Defense Advanced Research Projects Agency (DARPA), Medical CBRN Defense Consortium (MCDC) and the Department of Defense (DoD) Joint Program Executive Office (JPEO) for Chemical, Biological, Radiological and Nuclear Defense (CBRN), and we intend to continue entering into these types of agreements with government agencies in the future.
INO 10-Kaccession 0001055726-26-000008
SentenceWe have entered into agreements with government agencies, such as the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIH NIAID), Defense Advanced Research Projects Agency (DARPA), Medical CBRN Defense Consortium (MCDC) and the Department of Defense (DoD) Joint Program Executive Office (JPEO) for Chemical, Biological, Radiological and Nuclear Defense (CBRN), and we intend to continue entering into these types of agreements with government agencies in the future.
INO 10-Kaccession 0001055726-26-000008
SentenceWe have entered into agreements with government agencies, such as the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIH NIAID), Defense Advanced Research Projects Agency (DARPA), Medical CBRN Defense Consortium (MCDC) and the Department of Defense (DoD) Joint Program Executive Office (JPEO) for Chemical, Biological, Radiological and Nuclear Defense (CBRN), and we intend to continue entering into these types of agreements with government agencies in the future.
INO 10-Kaccession 0001055726-26-000008
SentenceWe have entered into agreements with government agencies, such as the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIH NIAID), Defense Advanced Research Projects Agency (DARPA), Medical CBRN Defense Consortium (MCDC) and the Department of Defense (DoD) Joint Program Executive Office (JPEO) for Chemical, Biological, Radiological and Nuclear Defense (CBRN), and we intend to continue entering into these types of agreements with government agencies in the future.
INO 10-Kaccession 0001055726-26-000008
Inovio Pharmaceuticals, Inc.
0.62
pre 1.98 +228.10%
Expected move
No implied move.